FDA Conference on Behind-the-counter status

On November 14th, the FDA heard comments from the general public-they are listed here. It's 88 pages long, just to warn you, but if you search for the name "Michael Mone" he spoke on behalf of APhA. He also has some Minnesota ties as well, so that's pretty nifty. Here is a more accessible format of the APhA statement.

I have not yet seen any replies from the FDA or any kind of summary. They are traditionally pretty slow moving, so I wouldn't expect any kind of movement for a while. However, on a slightly related note, Zyrtec is now available over the counter, and Zyrtec-D is behind the counter. As more medications like this are released, with both OTC and BTC status, the third class of drugs is essentially being created. But, will pharmacists take the opportunity to become more involved with their patient's health care when they aren't required to?